PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Go online to PeerView.com/NEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the roles of genomic testing and targeted treatment in lung cancer. Practical guidance for expanding molecular testing for genomic alterations occurring in non–small cell lung cancer with FDA-approved targeted therapies is explored. Upon completion of this activity, participants will be able to: Discuss the expanding role and increasing importance of broad genomic testing to identify molecular alterations that can guide the selection of matched targeted therapies for patients with NSCLC in the era of precision oncology, Describe new, emerging, and/or rare molecular alterations (eg, fusions, mutations, etc.) that are clinically relevant and therapeutically targetable in NSCLC, including NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others, and the latest testing methods/tools for identifying these alterations, Analyze data from clinical trials of precision therapies that target molecular alterations such as NTRK, RET, ROS1, and NRG1 fusions, MET and KRAS G12C mutations, HER2 mutations or overexpression, EGFR exon 20 insertions, and others in advanced NSCLC, Implement best practices and collaborative strategies for integration of wide-spread molecular testing and interpretation of results into oncology and pathology workflows in community and academic settings to ensure that appropriate patients with NSCLC with genomic alterations are identified and receive the most appropriate therapies in the context of clinical practice or clinical trials.

Go online to PeerView.com/NTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiology discusses best practices for the screening, diagnosis, and treatment of atrial fibrillation to reduce thromboembolic risk. Upon completion of this activity, participants will be able to: Recognize the prevalence of undiagnosed atrial fibrillation (AF) in patients 65 years and older at risk for AF and stroke, Discuss the need for opportunistic and systematic screening for AF among individuals 65 years of age and older and at high risk for AF and stroke, Employ various screening methods routinely in clinical practice to ensure that patients at risk for AF and stroke are diagnosed, Apply guideline recommendations as well as safety, efficacy, and real-world data on non–vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic risk reduction in patients with AF.

Go online to PeerView.com/YPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiology discusses the risk factors and symptoms associated with hyperkalemia and provides strategies to identify and manage these patients as well as methods for incorporating newer treatment options based on the latest evidence. Upon completion of this activity, participants should be better able to: Recognize the risk factors and clinical signs and symptoms associated with hyperkalemia, Identify different patient populations with or at risk for hyperkalemia and management strategies that address their specific needs and clinical goals of care, Incorporate newer treatment options for hyperkalemia management, including among patients with diabetes, heart failure, and chronic kidney disease (CKD), based on the latest evidence

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.